The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s interleukin inhibitors market report forecasts the interleukin inhibitors market size to grow to $68.56 Billion by 2027, with a CAGR (compound annual growth rate) of more than 16%.

Learn More On The Interleukin Inhibitors Market Report 2023 – https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report

Interleukin Inhibitors Market Size Forecast

The global interleukin inhibitors market is expected to grow from $31.73 billion in 2022 to $36.96 billion in 2023 at a compound annual growth rate (CAGR) of 16.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interleukin inhibitors market is expected to grow from $68.56 billion in 2027 at a CAGR of 16.7%.

North America held the largest interleukin inhibitors market share.

Key Interleukin Inhibitors Market Driver ­– Increase In The Number Of Investigational Drugs For Inflammatory Diseases

Inhibitors of interleukin decrease the actions of the inflammatory cytokines, stimulate innate immune responses to prevent damage to the host, and maintain normal tissue homeostasis. There are 48 molecules under investigation for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis. Among these, 20 molecules are in Phase III clinical trials. These growing numbers of pipeline drugs will drive the interleukin inhibitor market upon approval.

Request for A Sample Of The Global Interleukin Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3469&type=smp

Key Interleukin Inhibitors Market Trend – Developing Biosimilars

The patent expiration of biologic drugs creates opportunities for biosimilar drugs, which are a less expensive alternative. Major companies in the interleukin sector are focusing on developing biosimilars for interleukin inhibitors. For instance, biosimilars for IL inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx), among others, are in development by Mabpharm, NeuClone Pharmaceuticals Ltd., Gedeon Richter, and Bio-Thera Solutions, respectively. Despite the clinical benefits associated with the use of biologics in psoriasis and other autoimmune diseases, many patients are not treated with biological therapy, and access to treatment may be limited for several reasons, including higher treatment costs. This factor, coupled with rapid advances in biotechnology and analytical sciences that ensure comparability of biosimilars to biological drugs, drives the trend for biosimilars.

Interleukin Inhibitors Market Segment

1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6, Other Types

2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Interleukin Inhibitors Market Major Players and Strategies

Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals.

The Interleukin Inhibitors Global Market Report 2023 covers regional data on interleukin inhibitors market size, interleukin inhibitors market trends and drivers, opportunities, strategies, and interleukin inhibitors market competitor analysis. The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Interleukin inhibitors refer to a substance used to suppress the immune system that prevents interleukins from working. Interleukins are a class of cytokines produced by white blood cells in response to infection (lymphocytes, monocytes, and macrophages). They are crucial to the control of the immune system.

View More Reports Related To The Interleukin Inhibitors Market –

Checkpoint Inhibitors Global Market Report 2023

Protein Inhibitors Global Market Report 2023

Oral Biologics & Biosimilar Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: